New study in The Oncologist supports the use of blood-based tumor DNA (liquid biopsies) in hepatocellular carcinoma (HCC) to facilitate personalized medicine. The CureMatch decision support platform matches personalized drug combinations for liver cancer patients. SAN DIEGO, CA – March 26, 2018: A new cancer study[1] reports that next-generation sequencing of circulating tumor DNA (ctDNA) can provide therapeutically […]
